Sugi Predict

Sugi Predict / Compounds / SCHEMBL259183

SCHEMBL259183

SCHEMBL259183

Cc1cccc(OCCN2CCOCC2)c1

nearest known ligand 0.86

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.63
▸ L3MBTL1 Q9Y468 3/20 0.63
▸ ALDH1A1 P00352 4/20 0.63
▸ NPC1 O15118 1/20 0.63
▸ HTT P42858 1/20 0.63
▸ HSD17B10 Q99714 1/20 0.62
▸ TSHR P16473 2/20 0.61
▸ SMN1; SMN2 Q16637 1/20 0.61
▸ NPSR1 Q6W5P4 1/20 0.61
▸ KMT2A Q03164 2/20 0.61
▸ TP53 P04637 1/20 0.61
▸ MEN1 O00255 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4124442 0.93 KDM4E (0.74) KDM4EL3MBTL1ALDH1A1HTTHSD17B10
SCHEMBL14692962 0.90 ALDH1A1 (0.76) KDM4EL3MBTL1ALDH1A1HTTHSD17B10
SCHEMBL14578276 0.88 ALDH1A1 (0.69) KDM4EALDH1A1NPC1HTTTSHR
SCHEMBL14426319 0.86 KDM4E (0.78) KDM4EL3MBTL1ALDH1A1HTTTSHR
SCHEMBL8361480 0.86 KDM4E (0.83) KDM4EL3MBTL1ALDH1A1HTTTSHR
SCHEMBL12810770 0.85 KMT2A (0.69) KDM4EL3MBTL1ALDH1A1HTTSMN1; SMN2
SCHEMBL259391 0.85 KDM4E (0.86) KDM4EL3MBTL1ALDH1A1HTTTSHR
SCHEMBL13107094 0.84 ALDH1A1 (0.73) KDM4EALDH1A1NPC1HTTTSHR
SCHEMBL14570561 0.84 NPC1 (0.65) KDM4EALDH1A1NPC1KMT2AMEN1
SCHEMBL11941565 0.83 ALDH1A1 (0.77) KDM4EALDH1A1NPC1HTTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4219465-A2 PRMT5 INHIBITORS AND USES THEREOF Epizyme Inc (US) 2023-08-02 — — EP disclosed
US-20230148005-A1 MACROCYCLIC COMPOUNDS AND USES THEREOF THESEUS PHARMACEUTICALS, INC. 2023-05-11 — — US disclosed
EP-3498701-B1 PRMT5 INHIBITORS AND USES THEREOF EPIZYME INC (US) 2023-02-22 — — EP disclosed
US-20220133736-A1 USES OF PYRIMIDOPYRIMIDINONES AS SIK INHIBITORS THE GENERAL HOSPITAL CORPORATION (US) 2022-05-05 — — US disclosed
US-20200338087-A9 USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS DANA-FARBER CANCER INSTITUTE, INC. (US) 2020-10-29 — — US disclosed
US-20190343842-A1 USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS DANA-FARBER CANCER INSTITUTE, INC. (US) 2019-11-14 — — US disclosed
EP-3549934-A1 HETEROARYL COMPOUNDS AND USES THEREOF Celgene CAR LLC (BM) 2019-10-09 — — EP disclosed
EP-3536323-A1 USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS Dana Farber Cancer Institute, Inc. (US) 2019-09-11 — — EP disclosed
EP-2935247-B1 PRMT5 INHIBITORS AND USES THEREOF EPIZYME INC (US) 2019-08-28 — — EP disclosed
EP-3498701-A1 PRMT5 INHIBITORS AND USES THEREOF Epizyme Inc (US) 2019-06-19 — — EP disclosed
US-20070191447-A1 Novel heterocyclic compound DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-08-16 — — US disclosed
US-20070123521-A1 Cinnamoyl derivatives and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-05-31 — — US disclosed
US-20070123521-A1 Cinnamoyl derivatives and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-05-31 — — US disclosed
US-20070037805-A1 Fused heteroaryl derivatives HAYAKAWA MASAHIKO 2007-02-15 — — US disclosed
US-20070037805-A1 Fused heteroaryl derivatives HAYAKAWA MASAHIKO 2007-02-15 — — US disclosed
US-7173029-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2007-02-06 — — US disclosed
US-7173029-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2007-02-06 — — US disclosed
US-20070010515-A1 [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2007-01-11 — — US disclosed
US-20070010515-A1 [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2007-01-11 — — US disclosed
US-20070004675-A1 Inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE, INC. 2007-01-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230148005-A1 MACROCYCLIC COMPOUNDS AND USES THEREOF EGFR, ERBB2, ERBB3 KDM4E 2113/4885L3MBTL1 1252/4885ALDH1A1 2665/4885
US-20190343842-A1 USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS SIK1, SIK3, SIK2 KDM4E 752/4885L3MBTL1 4559/4885ALDH1A1 3380/4885
US-20070010515-A1 [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof HLA-C, TPMT, TAP1 KDM4E 2344/4885L3MBTL1 1326/4885ALDH1A1 208/4885
US-20070004675-A1 Inhibitors of VEGF receptor and HGF receptor signaling HGF, MET, FLT1 KDM4E 4094/4885L3MBTL1 4202/4885ALDH1A1 1649/4885
US-20070191447-A1 Novel heterocyclic compound OPRD1, GRIN3A, GRM3 KDM4E 2970/4885L3MBTL1 4071/4885ALDH1A1 1154/4885
US-20220133736-A1 USES OF PYRIMIDOPYRIMIDINONES AS SIK INHIBITORS SIK2, SIK1, SIK3 KDM4E 1681/4885L3MBTL1 4587/4885ALDH1A1 1744/4885
US-20070037805-A1 Fused heteroaryl derivatives PIK3CD, PIK3R3, PIK3C2A KDM4E 2196/4885L3MBTL1 3535/4885ALDH1A1 4428/4885
US-20070123521-A1 Cinnamoyl derivatives and use thereof CES2, EBP, CPT1A KDM4E 3010/4885L3MBTL1 4147/4885ALDH1A1 31/4885
US-20200338087-A9 USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS SIK1, SIK3, SIK2 KDM4E 752/4885L3MBTL1 4559/4885ALDH1A1 3380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.